EMINENT supports Multiple Groundbreaking Studies Exploring the Role of Semaglutide and Tirzepatide in Clinical Trials

FREDERICK, MD, UNITED STATES, January 7, 2025 / EINPresswire.com / -- EMINENT Services Corporation is at the forefront of innovative clinical trials exploring the potential of semaglutide and tirzepatide—FDA-approved medications for Type 2 diabetes and weight management—as adjunct therapies to reduce physiological dependence and opioid use in individuals with Opioid Use Disorder (OUD). Beyond this, EMINENT is actively involved in numerous other GLP-1 clinical trials, investigating the transformative potential of these medications across various health conditions. Read more here